Pentahibe by Pharmacosmos
Pentahibe is developed and manufactured by Pharmacosmos, a global leader in pharmaceutical-grade carbohydrates with more than 60 years of experience. Our expertise in carbohydrate chemistry, cGMP manufacturing and regulatory compliance forms the foundation of every Pentahibe formulation, giving researchers and developers confidence from early research through commercial manufacturing. Pharmacosmos supplies pharmaceutical-grade carbohydrates to customers in more than 50 countries worldwide and is the only manufacturer with both US FDA and EU approval for pharmacopeial carbohydrates, including the cryoprotective agent used in Pentahibe (pentaisomaltose).
Pharmacosmos complies with the highest current Good Manufacturing Practice (cGMP) requirements for human medicines. This is your assurance that all our products are of the highest quality and fit for their intended use.
We continuously optimise all relevant processes across production, documentation, control, and quality. And we validate and qualify our processes, equipment, and methods of analysis to ensure our products provide consistent quality, purity, safety, and efficacy, with minimum batch variation.
We also provide all the quality assurance documentation you need for the regulatory submission process, such as batch certifications, batch-to-batch reproducibility, toxicity reports, and access to US Drug Master files (DMF).
We are the only carbohydrate manufacturer certified by both the United States Food & Drug Administration (US FDA) and the European Directorate for the Quality of Medicines (EDQM).
Our facility and systems are inspected by national and international health authorities, including the Danish Medicines Agency (Lægemiddelstyrelsen) and the US FDA. And we do everything we can to exceed our customers’ expectations and monitor changing requirements to ensure the quality, safety and efficacy of our products.
From our ingredients to our waste management and power sources, we are working to ensure the environmental impact of our activities is kept to a minimum. The actions we take to protect and preserve nature are central to our daily business, and the production of PentaHibe.
Our Sustainability Ambition: Net Zero Carbon Emissions by 2045*
Our near-term carbon emission targets:
Reduce absolute scope 1 and 2 emissions by 55% in fiscal year 32/33 versus 22/23 base year
1 Engage at least 74% of scope 3 suppliers (by spend) to have science-based targets by FY29/30
2
Our long-term net zero target:
Reduce absolute scope 1, 2 and 3 emissions to achieve net zero by 2045
3
*Our near- and long-term goals are developed based on a carbon dioxide inventory conforming to the GHG Protocol standard and in accordance with the Paris Agreement adopted by the UN.
SBTi-approved targets
Our near-term/ net-zero target has been validated by the Science Based Targets initiative (SBTi). This independent validation confirms that our emissions reduction pathway is aligned with the latest climate science and the level of decarbonization required to help limit global warming. It reflects our long-term commitment to responsible manufacturing and supporting more sustainable supply chains for our customers.
- Pharmacosmos A/S
- Roervangsvej 30
- DK-4300 Holbaek
- Denmark
- Tel: +45 5948 5959
- Email: pentahibe@pharmacosmos.com
- Business hours are Monday to Friday 08:00-16:00 CET